Insilico Medicine · Series E
Accelerating drug discovery and development through generative AI and advanced bioinformatics platforms.
Amount
$110M
Round
Series E
Valuation
—
Announced
Mar 2025
Investors
Lead investor
Value Partners GroupNotes
funding refresh